Posts

PureTech Spins Off Celea with $180M Funding to Advance IPF Drug Deupirfenidone into Phase 3

on

Insilico's Rentosertib Inhalation Solution Receives IND Clearance for World's First AI-Driven Direct-to-Lung Clinical Study

on

Avalyn Pharma Aims for $182M IPO to Fund Phase 3 Trials of Inhaled Respiratory Drugs

on

Boehringer Ingelheim Breaks Decade-Long Drought with FDA Approval of Jascayd for Idiopathic Pulmonary Fibrosis

on

United Therapeutics' Tyvaso Succeeds in Phase 3 IPF Trial, Marking Major Advance in Lung Disease Treatment

on

PureTech Spins Out Celea Therapeutics to Advance IPF Drug Candidate

on

Pliant Therapeutics Discontinues Phase 2b/3 Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis Due to Safety Concerns

on

Pliant Therapeutics Halts Key Fibrosis Drug Trial, Stock Plummets Amid Uncertainty

on

Boehringer Ingelheim's Nerandomilast Achieves Second Phase III Success in Pulmonary Fibrosis Treatment

on

Pliant Therapeutics Halts Phase 2b/3 Idiopathic Pulmonary Fibrosis Trial Following Safety Committee Recommendation

on